trending Market Intelligence /marketintelligence/en/news-insights/trending/sacrZHnEn2H7nxcQTRHuaw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bayer, Evotec expand women's health collaboration to new disease target

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Bayer, Evotec expand women's health collaboration to new disease target

German companies Evotec SE and Bayer AG expanded their partnership in women's health with a new five-year collaboration to develop multiple potential treatments for polycystic ovary syndrome.

This common hormonal disorder affects women of reproductive age who may have infrequent or prolonged menstrual periods or excess male hormone levels. The ovaries may develop numerous small collections of fluid and fail to regularly release eggs.

Evotec will receive a €6.5 million up-front payment and €10 million in research payments over five years through the expanded partnership. The company may also be eligible to receive preclinical, clinical and sales milestones of over €330 million as well as royalties of net sales.

As part of the agreement, both companies will be responsible for drug targets and technology platforms to jointly develop the drug candidates. Evotec and Bayer will work together during the preclinical development of the potential therapies, while Bayer alone will take over on any subsequent clinical development and commercialization. Bayer will also have access to targets from a recent partnership between Celmatix Inc. and Evotec through the expanded deal.

Evotec and Bayer entered into an initial strategic five-year collaboration in 2012, through which the companies are developing a potential treatment of endometriosis. The disorder causes tissue similar to that which forms the lining of the uterus to grow outside of the uterine cavity. The companies also collaborated in 2016 to develop potential drugs for kidney diseases.